1: Hydroxyethyl starch 130/0.4, 6 %

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage

Drug Information

Target Indication

Plasma Volume Substitution (Hypovolemia) Including Massive Hemorrhage

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

FMS

Fresenius Medical Care AG

Related Pipeline

General Anesthesia

Nutrition Therapy

Parenteral Nutrition

Chronic Kidney Failure

Postmenopausal Osteoporosis